News

Newton, MA. Jan 11, 2018 – The Xcede Patch clinical trial dossier was submitted today to the Medical Ethical Review Committee (MREC) Universitair Medisch Centrum Groningen (Netherlands), in anticipation of a first-in-human clinical trial. The clinical trial, which outlines the treatment of up to 30 patients undergoing various types of liver resection, will take place at two major liver surgery centers in The Netherlands. Subject to the MREC approvals, the Company anticipates that patients will be treated with the Xcede Patch in the Netherlands in early 2018.

Newton, MA, August 10, 2017 –Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received two Phase II grants totaling $2.1 million under the National Institute of Health and NASA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

Newton, MA, August 2, 2017 –Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received three Phase II grants totaling $3.5 million under the Department of Energy’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

RMD collaborated with NASA on growing crystals of CLYC gamma-neutron scintillator crystals in microgravity.

Dynasil is very excited to announce that key scintillation crystal research done by its subsidiary RMD is included in the payload of CASIS Orbital ATK CRS-7 en-route to the International Space Station.

Dynasil hosted its annual meeting on February 23rd, 2017 in Watertown, MA on the campus of its RMD subsidiary. The meeting included presentations by President and CEO, Peter Sulick, President of RMD, Dr. Kanai Shah and CEO of Xcede, Dr. Linda Zuckerman.

Newton, MA, February 13, 2017 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced earnings attributable to common stockholders of $2.8 million or $0.17 per common share for the first quarter of the 2017 fiscal year, largely as the result of a U.S. income tax benefit resulting from the deconsolidation for tax purposes of Xcede Technologies, Inc., the Company’s tissue sealant technology development joint venture.

Company to Webcast Conference Call Live at 5:00 p.m. ET on February 14

Newton, Mass., February 9, 2017 – Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the fiscal quarter ended December 31, 2016 on Monday, February 13 and management will host a conference call for investors and analysts the following day, February 14, 2017 at 5:00 p.m. ET.

Newton, MA, December 21, 2016 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced net income of $0.3 million and $0.04 per common share for the fiscal year ended September 30, 2016 and the filing of its Annual Report on Form 10-K.

Newton, MA, November 29, 2016 – Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received three Phase I and one Phase II grants totaling $1.9 million under the National Institute of Health’s SBIR funding program.